Technical Analysis for CLBS - Caladrius Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical CLBS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 2.23% | |
| Inside Day | Range Contraction | 2.23% | |
| Wide Bands | Range Expansion | 2.23% | |
| Lower Bollinger Band Touch | Weakness | 2.23% | |
| Fell Below 200 DMA | Bearish | 0.55% | |
| Hammer Candlestick | Bullish | 0.55% | |
| Earnings Movers | Other | 0.55% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 1% | about 12 hours ago | |
| Gap Up Closed | about 14 hours ago | |
| Gap Up Partially Closed | about 14 hours ago | |
| 2x Volume Pace | about 14 hours ago | |
| 1.5x Volume Pace | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/03/2021
Caladrius Biosciences, Inc. Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Banking Biopharmaceutical Cancer Immunotherapy Diabetes Cancer Immunotherapy Melanoma Cell Therapy Clinical Services Adult Stem Cell Immunotherapy Product Progenitor Cell Cord Blood Metastatic Melanoma Cancer Immunotherapy Product Infarction Myocardial Infarction Neos Acute Myocardial Infarction Treatment Of Metastatic Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.88 |
| 52 Week Low | 1.05 |
| Average Volume | 6,872,374 |
| 200-Day Moving Average | 1.89 |
| 50-Day Moving Average | 1.96 |
| 20-Day Moving Average | 2.11 |
| 10-Day Moving Average | 1.88 |
| Average True Range | 0.29 |
| ADX | 19.55 |
| +DI | 27.59 |
| -DI | 25.48 |
| Chandelier Exit (Long, 3 ATRs ) | 2.18 |
| Chandelier Exit (Short, 3 ATRs ) | 2.39 |
| Upper Bollinger Band | 2.64 |
| Lower Bollinger Band | 1.59 |
| Percent B (%b) | 0.23 |
| BandWidth | 49.74 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0531 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.15 | ||||
| Resistance 3 (R3) | 2.16 | 2.07 | 2.09 | ||
| Resistance 2 (R2) | 2.07 | 1.99 | 2.06 | 2.07 | |
| Resistance 1 (R1) | 1.95 | 1.94 | 1.91 | 1.94 | 2.06 |
| Pivot Point | 1.86 | 1.86 | 1.84 | 1.85 | 1.86 |
| Support 1 (S1) | 1.74 | 1.78 | 1.70 | 1.73 | 1.60 |
| Support 2 (S2) | 1.65 | 1.73 | 1.64 | 1.59 | |
| Support 3 (S3) | 1.53 | 1.65 | 1.57 | ||
| Support 4 (S4) | 1.52 |
